Spots Global Cancer Trial Database for stage iii nsclc
Every month we try and update this database with for stage iii nsclc cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Phase 2 Study of Dacomitinib in NSCLC | NCT04027647 | NSCLC Stage III... NSCLC Stage III... NSCLC Stage IV Recurrent NSCLC EGFR Positive N... | Dacomitinib | 18 Years - | National Cancer Centre, Singapore | |
| A Phase 2 Trial of Almonertinib With Concurrent Radiotherapy in The Treatment of Local Advanced EGFR-mutant NSCLC | NCT04636593 | Non Small Cell ... Stage III NSCLC EGFR Activating... | Almonertinib | 18 Years - | First People's Hospital of Hangzhou | |
| Induction Lorlatinib in Stage III Non-small Cell Lung Cancer | NCT05740943 | Stage III NSCLC Surgery | Lorlatinib | 18 Years - 75 Years | Guangdong Provincial People's Hospital | |
| Induction Lorlatinib in Stage III Non-small Cell Lung Cancer | NCT05740943 | Stage III NSCLC Surgery | Lorlatinib | 18 Years - 75 Years | Guangdong Provincial People's Hospital | |
| Erlotinib or Placebo Following Chemoradiotherapy (Chemo/RT) in Stage III Non-Small Cell Lung Cancer (NSCLC) | NCT00153803 | Carcinoma, Non-... Non-small Cell ... NSCLC | Erlotinib (tarc... Placebo | 18 Years - | Dartmouth-Hitchcock Medical Center | |
| Stage III NSCLC RWE in Chinese Patients | NCT04023812 | Carcinoma, Non-... | 18 Years - 130 Years | AstraZeneca | ||
| Chemoradiation Followed by Durvalumab in Poor Risk and/or Elderly Patients With Stage III NSCLC | NCT04441138 | Stage III Non-s... | Durvalumab | 18 Years - | Rush University Medical Center | |
| Individualized Dose Prescription in Advanced Stage Lung Cancer Patients Using Modern (Chemo)Radiotherapy | NCT01577212 | Stage III Non-s... Individualized ... | Individualized ... | 18 Years - 85 Years | Radboud University Medical Center | |
| Clinical Trial for Evaluating Efficacy and Safety of PDR001 in Concurrent Plus Consolidation Versus Consolidation Only in Addition to Standard Chemoradiotherapy in Unresectable Stage III NSCLC Patients (PASTURE) | NCT03945227 | Stage III NSCLC | standard platin... PDR001 concurre... | 18 Years - | Yonsei University | |
| Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer | NCT05403385 | Metastatic NSCL... Stage III NSCLC | inupadenant Placebo Carboplatin Pemetrexed | 18 Years - | iTeos Therapeutics | |
| Erlotinib or Placebo Following Chemoradiotherapy (Chemo/RT) in Stage III Non-Small Cell Lung Cancer (NSCLC) | NCT00153803 | Carcinoma, Non-... Non-small Cell ... NSCLC | Erlotinib (tarc... Placebo | 18 Years - | Dartmouth-Hitchcock Medical Center | |
| A Phase 2 Trial of Almonertinib With Concurrent Radiotherapy in The Treatment of Local Advanced EGFR-mutant NSCLC | NCT04636593 | Non Small Cell ... Stage III NSCLC EGFR Activating... | Almonertinib | 18 Years - | First People's Hospital of Hangzhou | |
| Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer | NCT05403385 | Metastatic NSCL... Stage III NSCLC | inupadenant Placebo Carboplatin Pemetrexed | 18 Years - | iTeos Therapeutics |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
